Dr. Reddy's Laboratories Limited
NYSE:RDYDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $12.48B
- Beta
- 0.26
- P/E (TTM)
- 24.7
- EPS (TTM)
- $51.40
- Dividend yield
- 0.63%
Volume 1.79M
Average 2.39M
RDY Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Dr. Reddy's Laboratories LimitedNYSE: RDY
Accounts Payables · Q2 FY2027 · quarter ended Sep 2026
Accounts payables turns negative
Q2 FY2027 accounts payables was -₹2.45B, compared with ₹0 a year earlier. Trailing-twelve-month accounts payables was -₹7.14B.
Context
- Accounts payables amounted to 0.8% of revenue in FY2026, up 0.8 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -₹2.45B or moves back toward the trailing-twelve-month quarterly average of -₹1.79B.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
INR · from the cash flow
- Latest · FY2026
- 2.94B INR
- Year-over-year change
- —
- 4-year CAGR
- -35.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 2.94B | — |
| FY2025 | 2025-03-31 | 0 | — |
| FY2024 | 2024-03-31 | 0 | — |
| FY2023 | 2023-03-31 | 0 | -100.0% |
| FY2022 | 2022-03-31 | 17.01B | — |
Accounts Payables vs competitors
How RDY compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Accounts payables amounts to 2.2% of revenue for RDY, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹7.14B INR | — | — | 2.2% | |
| LTM Jun 2026 | $366.12M USD | -275.5% | +1.0% | 3.4% | |
| FY2025 | £122.26M GBP | — | -31.9% | 1.1% | |
| LTM Jun 2026 | $33.2M USD | +115.8% | — | 0.2% | |
| LTM Jun 2026 | $30.41M USD | -34.0% | -42.1% | 1.0% | |
| LTM Mar 2026 | $14.97M USD | +372.2% | +44.4% | 1.6% | |
| LTM Mar 2026 | $12.56M USD | -121.6% | +83.7% | 1.7% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding RDY) | — | -34.0% | +1.0% | 1.1% | |
Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 23.57B | 45.07B | 55.68B | 57.25B | 45.09B |
| Depreciation & Amortization | 11.82B | 12.64B | 14.84B | 17.06B | 21.68B |
| Deferred Income Tax | 8.73B | 15.3B | 16.19B | 19.54B | 0 |
| Stock-Based Compensation | 592M | 397M | 407M | 424M | 0 |
| Change in Working Capital | (13.91B) | (7.86B) | (20.18B) | (29.99B) | (12.24B) |
| Accounts Receivables | (17.01B) | (5.75B) | (8.05B) | (10.28B) | (7.07B) |
| Inventory | (5.33B) | (2.65B) | (18.45B) | (12.75B) | (9.05B) |
| Accounts Payables | 17.01B | 0 | 0 | 0 | 2.94B |
| Other Working Capital | (8.59B) | 551M | 6.32B | (6.95B) | 943.83M |
| Other Non-Cash Items | (2.69B) | (6.67B) | (21.5B) | (17.85B) | 2.12B |
| Operating Cash Flow | 28.11B | 58.88B | 45.43B | 46.43B | 56.65B |
| Capital Expenditures | (19.05B) | (18.87B) | (27.44B) | (34.4B) | (24.54B) |
| Acquisitions (Net) | (326M) | 0 | (12M) | (53.41B) | (2.99B) |
| Purchases of Investments | (88.97B) | (136.17B) | (145.49B) | (254.46B) | (49.21B) |
| Sales of Investments | 77.77B | 112.81B | 129.78B | 279.58B | 20.63B |
| Other Investing Activities | 4.19B | (6.68B) | (8.16B) | (2.28B) | 1.47B |
| Investing Cash Flow | (26.39B) | (41.37B) | (40.28B) | (58.08B) | (70.53B) |
| Debt Repayment | 2.74B | (20.4B) | 4.35B | 23.2B | 21.31B |
| Common Stock Issued | 334M | 368M | 805M | 193M | 417.73M |
| Common Stock Repurchased | 0 | 0 | 0 | (1.39B) | 0 |
| Dividends Paid | (4.15B) | (4.98B) | (6.65B) | (6.66B) | (7.01B) |
| Other Financing Activities | (1.35B) | (1.85B) | (2.27B) | 3.57B | (1.33B) |
| Financing Cash Flow | (2.42B) | (26.86B) | (3.76B) | 18.91B | 13.4B |
| Effect of Forex Changes | 733M | 286M | (59M) | 224M | (383.41M) |
| Net Change in Cash | 32M | (9.07B) | 1.33B | 7.49B | (875.84M) |
| Free Cash Flow | 9.06B | 40.01B | 18B | 12.03B | 32.1B |
Dr. Reddy's Laboratories Limited
NYSE:RDY
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.